Req ID:  47712

Tranent, ELN, GB, EH33 2NE

For 70 years, Charles River employees have worked together to assist in the discovery, development and safe manufacture of new drug therapies. When you join our family, you will have a significant impact on the health and well-being of people across the globe. Whether your background is in life sciences, finance, IT, sales or another area, your skills will play an important role in the work we perform. In return, we’ll help you build a career that you can feel passionate about.

Job Summary

The Department of Regulatory ADME and Discovery Sciences provides support to the pharmaceutical, veterinary pharmaceutical and chemical/agrochemical industries by evaluating the metabolism and disposition (ADME) of new chemical and biological entities in vitro and in vivo in a variety of test species. 

We are looking to recruit an experienced Scientist to join the in vitro metabolism team.


Key Responsibilities:

  • Act as Study Director on assigned studies
  • Design and conduct of in vitro metabolism studies to support compound registration
  • Data review and preparation of scientific reports suitable for regulatory submission
  • Establishing strong client relationships
  • Contributing to staff training and development programs
  • Supervision of junior staff
  • Ensuring a high quality of work from enquiry to study completion


Applicants should have:

  • A degree in a Life Science subject, ideally with a strong drug metabolism component
  • A significant level of hands on experience in the conduct of in vitro metabolism studies
  • A clear understanding of the requirements for both novel pharmaceutical and chemical registration
  • A keen eye for detail and the ability to focus on clear study outcomes


All internal applicants should apply through the careers page on Talent Hub.

The closing date for this position is Friday, 07 February 2020.

About Safety Assessment
Charles River is committed to helping our partners expedite their preclinical drug development with exceptional safety assessment services, state-of-the-art facilities and expert regulatory guidance. From individual specialty toxicology and IND enabling studies to tailored packages and total laboratory support, our deeply experienced team can design and execute programs that anticipate challenges and avoid roadblocks for a smooth, efficient journey to market.  Each year approximately 120 investigational new drug (IND) programs are conducted in our Safety Assessment facilities.


About Charles River
Charles River is an early-stage contract research organization (CRO). We have built upon our foundation of laboratory animal medicine and science to develop a diverse portfolio of discovery and safety assessment services, both Good Laboratory Practice (GLP) and non-GLP, to support clients from target identification through preclinical development. Charles River also provides a suite of products and services to support our clients’ clinical laboratory testing needs and manufacturing activities. Utilizing this broad portfolio of products and services enables our clients to create a more flexible drug development model, which reduces their costs, enhances their productivity and effectiveness to increase speed to market.

With over 14,000 employees within 80 facilities in 20 countries around the globe, we are strategically positioned to coordinate worldwide resources and apply multidisciplinary perspectives in resolving our client’s unique challenges. Our client base includes global pharmaceutical companies, biotechnology companies, government agencies and hospitals and academic institutions around the world. And in 2018, revenue increased by 22% to $2.27 billion from $1.86 billion in 2017.

At Charles River, we are passionate about our role in improving the quality of people’s lives. Our mission, our excellent science and our strong sense of purpose guide us in all that we do, and we approach each day with the knowledge that our work helps to improve the health and well-being of many across the globe. We have proudly supported the development of ~85% of the drugs approved by the FDA in 2018.